A study of AK138D1 for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You are able to get out of bed and do light activities (ECOG 0-1).
- You have a cancer that can be measured with scans (like CT or MRI).
- You have not had treatment that targets the HER3 protein before.
- You do not have active brain metastases, active hepatitis B or C, tuberculosis, or syphilis.
- You have not had a live vaccine in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK138D1 for people with advanced solid tumors that have not responded to or can't tolerate standard treatments. The goal is to see if it is safe and effective.
This study tests an experimental drug (AK146D1) for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
This trial tests a new drug called AK132 for people with advanced solid tumors. It looks at safety and how well the drug works, and may be an option if you have not already tried treatments targeting CD47 or Claudin18.2.
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
Hear when a new Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.